Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Abbott Laboratories    ABT

ABBOTT LABORATORIES

(ABT)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Summary
  • The company has strong fundamentals. More than 70% of listed companies have a lower mix of growth, profitability, debt and visibility criteria.
  • In a short-term perspective, the company has interesting fundamentals.
Strengths
  • The company returns high margins, thereby supporting business profitability.
  • Growth remains a strong point in this company. In their sales forecast, analysts sound optimistic with regard to sales prospects.
  • Over the last seven days, analysts have been revising upwards their EPS estimates for the company.
  • For the last 4 months, the company has been enjoying highly positive EPS revisions, which were frequently and significantly raised.
  • Analysts covering this company mostly recommend stock overweighting or purchase.
  • The tendency within the weekly time frame is positive above the technical support level at 87.14 USD
Weaknesses
  • Stock prices approach a strong long-term resistance in weekly data at USD 110.79.
  • The stock is close to a major daily resistance at USD 111.29, which should be gotten rid of so as to gain new appreciation potential.
  • Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
  • The company's enterprise value to sales, at 5.9 times its current sales, is high.
  • With an expected P/E ratio at 43.44 and 33.78 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
  • The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
Ratings chart
Sector Medical Equipment, Supplies & Distribution - NEC
1st jan.Capitalisation (M$)Investor Rating
ABBOTT LABORATORIES22.52%188 420
MEDTRONIC PLC-9.57%137 923
BECTON, DICKINSON AND COMPA..-13.27%68 377
HOYA CORPORATION22.44%45 978
BAXTER INTERNATIONAL INC.-6.54%39 562
SARTORIUS STEDIM BIOTECH120.31%35 264
ALIGN TECHNOLOGY, INC.57.51%34 628
DEXCOM, INC.59.61%33 525
TERUMO CORPORATION2.03%28 658
ZIMMER BIOMET HOLDINGS-10.90%27 614
WEST PHARMACEUTICAL SERVICE..86.42%20 717
SYSMEX CORPORATION37.47%20 506
AMERISOURCEBERGEN CORPORATI..12.56%19 536
BIO-RAD LABORATORIES, INC.51.19%16 685
STERIS PLC17.19%15 192
LIVONGO HEALTH, INC.480.21%14 585
More Results
Financials (USD)
Sales 2020 33 885 M - -
Net income 2020 4 415 M - -
Net Debt 2020 11 438 M - -
P/E ratio 2020 43,4x
Yield 2020 1,36%
Capitalization 188 B 188 B -
EV / Sales 2020 5,90x
EV / Sales 2021 5,13x
Nbr of Employees 107 000
Free-Float 88,8%
Upcoming event on ABBOTT LABORATORIES
Notations Surperformance©
  Help  
Fundamental ratings
Overall rating
Trading Rating
Investor Rating
Growth (Revenue)
Valuation
Finances
Profitability
Earnings quality
Business Predictability
P/E ratio
Potential
Yield
Consensus
7 days EPS revision
4 months EPS revision
1 year EPS revision
4 months Revenue revision
1 year Revenue revision
Technical ratings
Short Term Timing
Middle Term Timing
Long Term Timing
RSI
Bollinger Spread
Unusual Volumes